Advances in chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma

Biomarker Research

Zixun Yin¹  Xin Wang²  Ya Zhang² 

[1] Department of Hematology, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, 250021, Jinan, Shandong, China;School of Medicine, Shandong University, 250021, Jinan, Shandong, China;Department of Hematology, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, 250021, Jinan, Shandong, China;School of Medicine, Shandong University, 250021, Jinan, Shandong, China;Department of Hematology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, 250012, Jinan, Shandong, China;Shandong Provincial Engineering Research Center of Lymphoma, 250021, Jinan, Shandong, China;Branch of National Clinical Research Center for Hematologic Diseases, 250021, Jinan, Shandong, China;National Clinical Research Center for Hematologic Diseases, the First Affiliated Hospital of Soochow University, 251006, Suzhou, China;

关键词: Chimeric antigen receptor T-cell therapy;    CAR-T-associated toxicities;    New targets;   

DOI  :  10.1186/s40364-021-00309-5

来源: Springer

【 摘 要 】

B-cell non-Hodgkin lymphoma (B-NHL) is a group of heterogeneous disease which remains incurable despite developments of standard chemotherapy regimens and new therapeutic agents in decades. Some individuals could have promising response to standard therapy while others are unresponsive to standard chemotherapy or relapse after autologous hematopoietic stem-cell transplantation (ASCT), which indicates the necessity to develop novel therapies for refractory or relapsed B-NHLs. In recent years, a novel cell therapy, chimeric antigen receptor T-cell therapy (CAR-T), was invented to overcome the limitation of traditional treatments. Patients with aggressive B-NHL are considered for CAR-T cell therapy when they have progressive lymphoma after second-line chemotherapy, relapse after ASCT, or require a third-line therapy. Clinical trials of anti-CD19 CAR-T cell therapy have manifested encouraging efficacy in refractory or relapsed B-NHL. However, adverse effects of this cellular therapy including cytokine release syndrome, neurotoxicity, tumor lysis syndrome and on-target, off-tumor toxicities should attract our enough attention despite the great anti-tumor effects of CAR-T cell therapy. Although CAR-T cell therapy has shown remarkable results in patients with B-NHL, the outcomes of patients with B-NHL were inferior to patients with acute lymphoblastic leukemia. The inferior response rate may be associated with physical barrier of lymphoma, tumor microenvironment and low quality of CAR-T cells manufactured from B-NHL patients. Besides, some patients relapsed after anti-CD19 CAR-T cell therapy, which possibly were due to limited CAR-T cells persistence, CD19 antigen escape or antigen down-regulation. Quite a few new antigen-targeted CAR-T products and new-generation CAR-T, for example, CD20-targeted CAR-T, CD79b-targeted CAR-T, CD37-targeted CAR-T, multi-antigen-targeted CAR-T, armored CAR-T and four-generation CAR-T are developing rapidly to figure out these deficiencies.

【 授权许可】

CC BY